Trial reportInternational ophthalmology2025
Efficacy of intense pulsed light therapy combined with eyelid margin cleaning using a deep cleaning device in the treatment of meibomian gland dysfunction: a randomized controlled trial.
Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe compared the efficacy of intense pulsed light (IPL) therapy alone and combined with eyelid margin cleaning using a deep cleaning device for the treatment of meibomian gland dysfunction (MGD).
methodsIn this single-center, investigator-masked randomized controlled trial, eyelid margin cleaning was performed using an OCUFACE device (Guangzhou Ocuface Biotechnology Co., Ltd.). Treatment efficacy was compared between the intervention and control groups based on changes in the clinical indicators from baseline. The primary outcomes were the improvement of meibomian gland secretion quality, changes in the Ocular Surface Disease Index (OSDI) score, and the improvement of tear film stability (e.g., tear break-up time).
resultsData from 120 eyes of 60 patients with MGD were included in the final analysis. The changes in the OSDI (p = 0.021) and nasal-region meibomian gland function (p = 0.022) differed significantly between groups. The change in temporal-region meibomian gland function had a similar trend, but the difference was not significant (p = 0.25). The mean value for lower-eyelid meibomian gland loss was significantly lower in the intervention group than in the control group (0.85 vs. 1.12, p = 0.045). The median NIBUT after treatment was significantly longer in the intervention group than in the control group (5.45 vs. 3.05 s, p = 0.008).
conclusionIPL therapy combined with deep eyelid margin cleaning alleviates meibomian gland orifice obstruction and improves tear film stability. This study establishes a new treatment paradigm, with a shift from passive thermal modulation to active ductal remodeling.
trial registrationThis research was retrospectively registered in the Chinese Clinical Trial Registry (CTR2400092860, 2024/11/25).
Indexed as
Identifiers
41385013What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.